Mayo Clinic researchers have uncovered how aging "zombie cells" trigger harmful inflammation that accelerates a severe and ...

The FDA has qualified AI-Based Histologic Measurement of NASH, or AIM-NASH — the first AI drug development tool — to assist ...

Mayo Clinic researchers have discovered how aging "zombie cells" contribute to inflammation that speeds up a serious form of ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...

Below, Pasquariello breaks down some of the benefits you can realistically expect from a supplement like Daily Dose, her ...

Microphysiological systems help address the shortcomings of animal models for mAb development, and CN Bio is taking an active ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), a spectrum of liver conditions ranging from simple steatosis to steatohepatitis (MASH), fibrosis, and cirrhosis, represents a global ...

Since its launch, Rezdiffra has made steady commercial progress. In the third quarter, Madrigal's single approved product ...

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...

The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their ...

PathAI, a global leader in AI-powered pathology, today announced that the U.S. Food and Drug Administration (FDA) has qualified AIM-MASH AI Assist through the Drug Development Tool (DDT) Biomarker ...